Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-07-13
2008-11-11
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S183000, C514S210020, C514S324000, C514S414000, C514S616000, C514S645000, C514S651000
Reexamination Certificate
active
07449453
ABSTRACT:
A method of prevention or treatment of a cholesterol-associated tumor is provided which comprises administering a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor, preferably ezetimibe (SCH 58235) and/or its phenolic glucuronide, or at least one ezetimibe analog, e.g., SCH 48461 and SCH 58053, to a patient wherein the patient is either at risk of developing a cholesterol-associated tumor or already exhibits a cholesterol-associated tumor. Formulations of ezetimibe are also provided for the prevention or treatment of a cholesterol-associated tumor further comprising at least one other anticancer agent. An article of manufacture is also provided which comprises a container, instructions, and a composition, wherein the composition comprises a therapeutically effective amount of an azetidinone-based cholesterol absorption inhibitor, preferably ezetimibe or its phenolic glucuronide, and the instructions are for the administration of the composition for the prevention or treatment of a cholesterol-associated tumor.
REFERENCES:
patent: 3622437 (1971-11-01), Hobaica et al.
patent: 4418068 (1983-11-01), Jones
patent: 4536516 (1985-08-01), Harper et al.
patent: 4623660 (1986-11-01), Richardson
patent: 4719207 (1988-01-01), Tamura et al.
patent: 4839155 (1989-06-01), McCague
patent: 5047431 (1991-09-01), Schickaneder et al.
patent: 5610150 (1997-03-01), Labrie
patent: 5613460 (1997-03-01), Stallard, III
patent: 5919815 (1999-07-01), Bradley et al.
patent: 5972383 (1999-10-01), Gibson et al.
patent: 6015806 (2000-01-01), Labrie et al.
patent: 6239167 (2001-05-01), Bissery
patent: 6245352 (2001-06-01), Arbuthnot et al.
patent: 6380405 (2002-04-01), Ekwuribe et al.
patent: 6395770 (2002-05-01), Broder et al.
patent: 6534540 (2003-03-01), Kindness et al.
patent: 6933292 (2005-08-01), Schaffner et al.
patent: 7098198 (2006-08-01), Schaffner et al.
patent: 2001/0041713 (2001-11-01), Waldstreicher et al.
patent: 2004/0146714 (2004-07-01), McCollum et al.
patent: 2006/0072372 (2006-04-01), Thomas et al.
patent: WO-93/02048 (1993-02-01), None
patent: WO 93/02048 (1993-02-01), None
patent: WO 94/17038 (1994-08-01), None
patent: WO-94/17038 (1994-08-01), None
patent: WO 95/08532 (1995-03-01), None
patent: WO-95/08532 (1995-03-01), None
Webster's II New Riverside University Dictionary, published 1984, pp. 933 and 1208.
Hawk et al., Primary Cancer Prevention Trials, Hematology/Oncology Clinics of North America, vol. 14, No. 4, Aug. 2000, pp. 809-830.
Hawk, E.T. et al., “Primary Cancer Prevention Trials”, Understanding Clinical Trials, Hematology/Oncology Clinics of North America, Aug. 2000, pp. 809-830, vol. 14, No. 4, USA.
Gordon, H.W. et al., “The Effect of Polyene Macrolides on the Prostate Gland and Canine Prostatic Hyperplasia”, Applied Biology, Aug. 1968, pp. 1201-1208, vol. 60, No. 4.
Schaffner, C.P. et al., “The Hypocholesterolemic Activity of Orally Administered Polyene Macrolides”, Applied Biology, Sep. 1968, pp. 36-41, vol. 61, No. 1.
Medical Tribune Article, “Prostate Hypertrophy Laid to Cholesterol”, Sep. 22, 1976, p. 23.
Sporer, A. et al., “Candicidin: Physiologic Effect on Prostate”, Urology, Sep. 1975, pp. 298-304, vol. 6, No. 3.
Orkin, L.A., “Efficacy of Candicidin in Benign Prostatic Hypertrophy”, Urology, Jul. 1974, pp. 80-84, vol. 4, No. 1.
Keshin, J.G., “Effect of Candicidin on the Human Benign Hypertrophied Prostate Gland”, International Surgery, February 1973, pp. 116-122, vol. 58, No. 2.
Kolonel, L.N. et al., “Dietary Fat and Prostate Cancer: Current Status”, Journal of the National Cancer Institute, Mar. 3, 1999, pp. 414-428, vol. 91, No. 5, Oxford University Press.
Willett, W., “The Search for the Causes of Breast and Colon Cancer”, Nature, Mar. 30, 1989, pp. 389-394, vol. 338.
Schaffner, C.P., “Nenign Prostatic Hypertrophy”, 1983, pp. 280-307, Frank Hinman, Jr. ed., Springer-Verlag, New York.
Haditirto, S., “The Effect of Oral Candicidin, a Heptaene Macrolide Antifungal Antibiotic, on the Lipid Metabolism of the Rat”, 1974, Ph.D. Dissertation, Rutgers University.
Wang, G.M. et al., “Effect of Candicidin and Colestipol on the Testes and Prostate Glands of Bio 87.20 Hamsters”, Investigative Urology, Jul. 1976, pp. 66-71, vol. 14, No. 1, The Williams & Wilkins Co., USA.
Swyer, G.I.M., “The Cholesterol Content of Normal and Enlarged Prostates”, Cancer Research, Feb. 1942, pp. 372-375, vol. 2.
Schaffner, C.P. et al., “Cholesterol and Cholesterol-a-Epoxide in Human Breast Secretions”, Cancer Detection Prevention, 1980, p. 143, vol. 3.
Sporer, A. et al., “Epoxycholesterols in Secretions and Tissues of Normal, Benign, and Cancerous Human Prostate Glands”, Urology, Sep. 1982, pp. 244-250, vol. 20, No. 3.
Petrakis, N.L. et al., “Cholesterol and Cholesterol Epoxides in Nipple Aspirates of Human Breast Fluid”, Cancer Research, Jun. 1981, pp. 2563-2565, vol. 41.
Wrensch, M.R. et al., “Breast Fluid Cholesterol and Cholesterol B-Epoxide Concentrations in Women with Benign Breast Disease”, Cancer Research, Apr. 15, 1989, pp. 2168-2173, vol. 49.
Homburger, F. et al., “Cystic Prostatic Hypertrophy in Two Inbred Lines of Syrian Hamsters”, Proc. Soc. Exptl. Biol. Med., 1970, pp. 284-286, vol. 134.
Schaffner, C.P. et al., “Absence of Cholesterogenesis Rehulation in the Liver and Prostate of the BIO 87.20 Hamster”, Lipids, Nov. 1981, pp. 835-840, vol. 16, No. 11.
Rosenblum, S.B. et al., “Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropl]-(4S)-(4-hydroxyphenyl)-2-azetidinone(SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption”, J. Med. Chem., 1998, pp. 973-980, vol. 41, No. 6, American Chemical Society.
Montero, A. et al., “Docetaxel for Treatment of Solid Tumours: A Systematic Review of Clinical Data”, Lancet Oncol., Apr. 2005, pp. 229-239, vol. 6.
Kucuk, O. et al., “Increased Plasma Level of Cholesterol-5B,6B-epoxide in Endometrial Cancer Patients”, Cancer Epidemiology Biomark. Prevention, Oct./Nov. 1994, pp. 571-574, vol. 3.
Reiss, P.et al., “An Enzymatic Synthesis of Glucuronides of Azetidinone-based Cholesterol Absorption Inhibitors”, Bioorganic Med. Chem., 1999, pp. 2199-2202, vol. 7.
Van Heek, M. et al., “Comparison of the Activity and Disposition of the Novel Cholesterol Absorption Inhibitor, SCH58235, and its Glucuronide, SCH60663”, British J. Pharm., 2000, pp. 1748-1754, vol. 129, No. 8, Macmillan Publishers Ltd.
Repa, J.J. et al., “Inhibition of Cholesterol Absorption by SCH 58053 in the Mouse is not Mediated via Changes in the Expression of mRNA for ABCA1, ABCG5, or ABCG8 in the Entercyte”, J. Lipid Research, 2002, pp. 1864-1874, vol. 3.
Freeman Michael R.
Schaffner Carl P.
Solomon Keith R.
Children's Medical Center Corporation
Henley, III Raymond J
Karykion Inc.
Mathews, Shepherd, McKay & Bruneau, P.A.
LandOfFree
Compositions of ezetimibe and methods for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions of ezetimibe and methods for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions of ezetimibe and methods for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4042387